These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

928 related items for PubMed ID: 26927900

  • 1. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL.
    Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW.
    Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
    [Abstract] [Full Text] [Related]

  • 7. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A, Bhandari S.
    Trials; 2019 Apr 04; 20(1):194. PubMed ID: 30947751
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT.
    Transfusion; 2009 Dec 04; 49(12):2719-28. PubMed ID: 19682342
    [Abstract] [Full Text] [Related]

  • 12. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O, Richard-Davis G, Morris T, Armstrong J.
    Clin Ther; 2007 Aug 04; 29(8):1682-91. PubMed ID: 17919549
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE, Lindstrøm JC, Jahnsen ME, Finnes E, Zoller H, Moum B, Jahnsen J.
    Aliment Pharmacol Ther; 2019 Aug 04; 50(4):397-406. PubMed ID: 31264261
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Iron (III) isomaltoside 1000.
    Mace TA, Syed A, Bhandari S.
    Expert Rev Hematol; 2013 Jun 04; 6(3):239-46. PubMed ID: 23782077
    [Abstract] [Full Text] [Related]

  • 18. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J.
    Clin J Am Soc Nephrol; 2014 Apr 04; 9(4):705-12. PubMed ID: 24458078
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C.
    Am J Gastroenterol; 2008 May 04; 103(5):1182-92. PubMed ID: 18371137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.